Abiopharma

COSMOS HEALTH INC. (COSM) Reports the reporting period Financial Results COSMOS HEALTH INC. (COSM) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 331926
• Net Income: (1,687,511
• EPS: Not disclosed
• Cash and equivalents: 2445168
  • rate, adding over 75 new pharmacies · Achieved pan
  • European distribution for Sky Premium Life through Skroutz, making products available across all 27 EU Member States · Signed a distribution agreement with International Medical Company for Qatar, whose Kulud Pharmacies arm is the country's largest chain, securing an initial order of 31,000 Sky Premium Life units · Received a third consecutive order from Pharmalink in the UAE for 60,000 Sky Premium Life units, taking cumulative orders to 270,000 United States Expansion · Introduced the "18 Series," a science
  • driven nutraceutical platform targeting a portfolio of 18 products. Initial focus areas include liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging · Entered the $163 billion global skincare market, with U.S. sales already underway 3 Contract Manufacturing · Cana Laboratories built its orderbook to an all
    • targeting $7.4 million in revenue and $5.3 million in gross profit · Entered the $69 billion global animal health industry with a veterinary formulation of C-Scrub Wash 4%, following successful testing under EN 1656
    • targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
    • targeting a portfolio of 18 products. Initial focus areas include liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging · Entered the $163 billion global skincare market, with U.S. sales already underway 3 Contract Manufacturing · Cana Laboratories built its orderbook to an all-time high of over 25 million units across nine therapeutic categories, under agreements extending up to ten years · Signed a 3.9 million-unit agreement with Verisfield for VASCLOR GEST progesterone pessaries · Signed a 2.86 million-unit agreement with Pharmex S.A. across three dermatological products · Received further orders from Nassington and Verisfield totalling 253,657 units across a range of medicines · Inaugurated a new capsule production line alongside a five-year agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN Clinical Validation and New Categories · C-Scrub Wash 4% successfully completed testing under EN 1279